New Research Points to a Better Biomarker for MSI mCRC New Research Points to a Better Biomarker for MSI mCRC

David J. Kerr, CBE, MD, DSc, discusses the potential for identifying patients who are likely to be more responsive to immune checkpoint inhibitors.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news